OncoMethylome Sciences SA to Initiate a Large Colorectal Cancer Clinical Trial

OncoMethylome Sciences to Acquire Minority Interest in Signature Diagnostics AG

31-Jan-2008

OncoMethylome Sciences announced that it plans to launch a large, international, multi-center colorectal cancer clinical trial. The German portion of the international trial will be managed by Signatures diagnostics. Signature Diagnostics will receive an upfront payment plus service fees for its contribution to the clinical trial. In addition, both companies also agreed that OncoMethylome Sciences will obtain first negotiation rights on a test in development by Signature Diagnostics for predicting outcomes in colorectal cancer patients. Subject to certain conditions that are standard for this type of transactions, OncoMethylome Sciences also agreed to acquire a minority interest in Signature Diagnostics.

Additional details and financial terms of the agreement were not disclosed.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures